Soligenix - Bathi saben siji saham sajrone 12 wulan pungkasan SNGX

Simbol resmi perusahaan Soligenix Inc (SNGX)

Soligenix, Inc. (SNGX) is actively developing its R&D portfolio of orphan drugs against biotreats, which impacts the annual EPS dynamics over a rolling year. The value of 79.80 characterizes this level, confirming the resilience of the model. Stability is ensured by production at GMP facilities in Europe and the US, while government defense orders amid geopolitical tensions guarantee demand for the drugs.

Soligenix (SNGX): Bathi resik saben saham (EPS TTM) saka 11.02.2024 nganti 15.11.2026

Soligenix Inc - rincian analitis lan metrik utama (SNGX)

- rega saham lan konsensus proyeksi valuasi:
Analisis wiwitan perusahaan:SNGX, BioPharma Bio
Produk sing diprodhuksi Soligenix

Year-over-year (YoY) EPS growth (TTM) reflects the percentage change in net income per share over the last twelve months, determining the scaling rate of the business's real income. For Soligenix, Inc. (SNGX), the rolling annual EPS YoY trend on GURU.Markets demonstrates the effectiveness of monetizing niche drugs, where the transition to mass production following certification directly confirms capital stability.